Description
Xultophy marries the benefits of Insulin Degludec, a long-acting basal insulin, with Liraglutide, a GLP-1 receptor agonist. Both active ingredients are derived using the recombinant DNA expression of Saccharomyces cerevisiae. The solution, clear and colorless, is housed in a 3mL single-patient-use, pre-filled pen, with each mL containing 100 units of Insulin Degludec and 3.6mg of Liraglutide.